About Us
Adastra is a private clinical-stage biopharmaceutical company focused on providing novel solutions to advance patient care in oncology. Our vision is to identify, develop and deliver important new therapies for cancers with significant unmet needs.
We deliver on this vision with our lead clinical candidate zotiraciclib, a potent oral kinase inhibitor that crosses the blood-brain barrier and possesses a unique mechanism of action. Adastra is actively identifying new products to develop that may offer enhanced options for patients underserved by existing therapies.
Highly Acclaimed Research
Adastra has multiple ongoing studies with leading research centers, including the National Cancer Institute (NCI) and the European Organisation for Research and Treatment of Cancer (EORTC).